Coverage, Formulary Restrictions, and Affordability of Sodium-Glucose Cotransporter 2 Inhibitors by US Insurance Plan Types.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 35977296.
- Also identified by DOI 10.1001/jamahealthforum.2021.4205 and PMC identifier 8796944.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This cross-sectional study evaluates the stipulations of coverage under commercial, health insurance exchange, Veterans Affairs, Medicare, Medicaid, or other insurance for canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.
Medical subject headings
- Diabetes Mellitus, Type 2
- Sodium-Glucose Transporter 2 Inhibitors
- Drug Costs
- Insurance, Health